{"type":"trials","record":{"id":42057,"source_id":"clinicaltrials-gov","external_id":"NCT06178770","title":"Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up","brief_summary":"This retrospective study included nAMD patients whose eyes were grouped into the following cohorts, with the overall cohort receiving ≥ 1 brolucizumab injection; the 12-month and 18-month brolucizumab (BRO) cohorts, which consisted of nAMD patient eyes who switched from a previous anti-vascular endothelial growth factor (VEGF) and had ≥3 brolucizumab injections with no other anti-VEGF in the first 12 months (360 days) and 18 months (540 days) of follow-up respectively; and the 12-month and 18-month alternating (ALT) cohorts, which consisted of nAMD patient eyes who switched from a previous anti-VEGF to brolucizumab and had ≥2 brolucizumab injections and ≥1 injection of another anti-VEGF in the first 12 months and 18 months of follow-up, respectively.","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":414,"countries":["United States"],"start_date":"2021-12-01","completion_date":"2022-12-12","last_update_date":"2023-12-21","source_url":"https://clinicaltrials.gov/study/NCT06178770","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":null,"organization":"Novartis","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change in injection interval from baseline to Month 12 for BRO and ALT cohorts — Baseline, Month 12","Change in injection interval from first brolucizumab injection to Month 18 for BRO and ALT cohorts — Baseline, Month 18","Change in visual acuity (VA) from first brolucizumab injection to Month 12 (for BRO and ALT cohorts) and Month 18 (for…","Change in central macular thickness (CMT) from first brolucizumab injection to Month 12 (for BRO and ALT cohorts) and M…","Age — Baseline","Gender — Baseline","Visual acuity (Early Treatment Diabetic Retinopathy Study [ETDRS] Letters) — Baseline, Month 12 and Month 18","Anti-VEGF treatment status — Baseline","Last injection interval before switch to brolucizumab in prior-treated eyes — Baseline","Central macular thickness (CMT) — Baseline, Month 12 and Month 18","Intraretinal fluid (IRF) — Baseline","Subretinal fluid (SRF) — Baseline","Pigment epithelial detachment (PED) — Baseline","Number of brolucizumab injections and non-brolucizumab injections from first brolucizumab injection to 12 months (for A…","Ocular adverse events (AEs) in eyes treated with at least one brolucizumab injection — Up to 3 years","Median time (days) from first brolucizumab injection to AE — Up to 3 years","Median time (days) from last brolucizumab injection pre-AE to AE — Up to 3 years","Median time (days) from AE to resolution — Up to 3 years","Median number of brolucizumab injections pre-AE including the index injection — Up to 3 years","Proportion of patients in different levels of vision recovery after AE resolution — Up to 3 years"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06178770","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-12-01 to 2022-12-12","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.913Z","intervention":[],"participants":414,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change in injection interval from baseline to Month 12 for BRO and ALT cohorts — Baseline, Month 12","Change in injection interval from first brolucizumab injection to Month 18 for BRO and ALT cohorts — Baseline, Month 18","Change in visual acuity (VA) from first brolucizumab injection to Month 12 (for BRO and ALT cohorts) and Month 18 (for…","Change in central macular thickness (CMT) from first brolucizumab injection to Month 12 (for BRO and ALT cohorts) and M…","Age — Baseline","Gender — Baseline","Visual acuity (Early Treatment Diabetic Retinopathy Study [ETDRS] Letters) — Baseline, Month 12 and Month 18","Anti-VEGF treatment status — Baseline","Last injection interval before switch to brolucizumab in prior-treated eyes — Baseline","Central macular thickness (CMT) — Baseline, Month 12 and Month 18","Intraretinal fluid (IRF) — Baseline","Subretinal fluid (SRF) — Baseline","Pigment epithelial detachment (PED) — Baseline","Number of brolucizumab injections and non-brolucizumab injections from first brolucizumab injection to 12 months (for A…","Ocular adverse events (AEs) in eyes treated with at least one brolucizumab injection — Up to 3 years","Median time (days) from first brolucizumab injection to AE — Up to 3 years","Median time (days) from last brolucizumab injection pre-AE to AE — Up to 3 years","Median time (days) from AE to resolution — Up to 3 years","Median number of brolucizumab injections pre-AE including the index injection — Up to 3 years","Proportion of patients in different levels of vision recovery after AE resolution — Up to 3 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42057","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}